Wegovy In The Wings, Novo Outlines Potential, Sizes Up Perceptions In India

Novo Nordisk India MD talks to Scrip about what to expect when Wegovy arrives in India and the local trajectory of Rybelsus. The Danish group also shared findings of a study around obesity.

L-R: Dr Muffazal Lakdawala, Dr Rishma Pai, Dr A G Unnikrishnan, Vikrant Shrotriya, Dr Maya Sharma

Novo Nordisk’s Wegovy (injectable semaglutide) is currently the rage as a treatment option for obesity. But the question on the mind of many in markets like India is when supplies will be available in the country.

Novo Nordisk India corporate vice-president and managing director, Vikrant Shrotriya, made it clear the company would have liked to launch...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Scrip

More from Leadership